Science Pool

Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach

Evotec SE announced today that the Company has expanded its neurodegeneration collaboration with Bristol Myers Squibb with the initiation of discovery and development efforts regarding a new strategy to tackle neurodegenerative diseases including Alzheimer’s through a novel approach to targeted protein degradation. Evotec receives payments totalling US$ 15 m from Bristol Myers Squibb.

Read More

Twitter
LinkedIn
Email
Generated by Feedzy